Purpose: To evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-CPC) in glaucoma patients and to assess differences among glaucoma subtypes.
Material and Methods: A retrospective study was conducted on 40 eyes of 35 patients with various types of glaucoma. Micropulse cyclophotocoagulation was indicated for glaucoma which was uncontrolled on maximum medical therapy. The procedures were performed using micropulse mode (2000 mW, 0.5 ms on, 1 ms off, mean energy 129.4 J). Follow-up examinations were conducted at 1 and 3 months and at 6–12 and 12–24 months. Success of treatment was defined as reduction of intraocular pressure (IOP) by ≥20%. A subgroup without modification of therapy was analyzed separately.
Results: Success rates were 33.3% at 1 month, 25.0% at 3 months, 35.3% at 6–12 months, and 30.0% at 12–24 months. Higher efficacy was observed in patients without modification of therapy (up to 41.7%). The most stable and sustained outcomes were seen in primary open-angle glaucoma, whereas secondary glaucomas and primary angle-closure glaucoma efficacy was short-term. Additional glaucoma surgery was required in 30% of eyes. No statistically significant change in best corrected visual acuity compared to baseline was observed at any follow-up interval, although a trend toward worsening was observed in the early time intervals.
Conclusion: MP-CPC demonstrates limited and variable efficacy. The outcomes depend on glaucoma type, baseline IOP, and modifications of treatment. The procedure appears relatively safe, although it may have a temporary impact on visual acuity.